Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: William B. Kohn who wrote (11956)	12/1/1997 9:57:00 PM
From: buyhiman	Respond to of 32384

re; Edge of the woods on these drugs Clincial trials are often not predictive of all significant adverse effects when a mass population of patients receives a new drug post-approval. This is problem Rezulin is now experiencing; perhaps the liver effects are only in subpopulations with particular suceptability. Only time and data will tell. Same situation occurred with Fen/Phen; never a mass marketing success Fen became much more popular when Redux form was released and combined with Phen in 100's of 1000's of patients. Same can happen with any innovative new therapy including Ligand's (if/when we reach market). What counts in long run is careful estimation of benefits vs risks with proper prescribing and adequate monitoring by physician's. Anyone who assumes all is hunky dorey forever more if FDA approves a drug is simply not educated to these facts. Just my opinion Carl R.